Cancer Research

Article	Citations
Abstract P1-13-04: Evaluation of the impact Vitamin D and Calcium supplementation on bone mineral density in breast cancer patients using or not taking Aromatase Inhibitors: 5-year follow-up	398
Abstract P4-12-09: Implications of protocol modifications and treatment delays for breast cancer patient experiences during Covid-19	180
Abstract P2-12-23: Changes in 18F-FDG-PET uptake after the first course of DTX reflect response to preoperative chemotherapy and prognosis in breast cancer	172
Abstract OT1-05-01: Glycoprotein 88 (GP-88) serum levels as a marker of response to therapy in patients with metastatic breast cancer	168
Abstract P3-19-16: Impact of targeted intraoperative (TARGIT-IORT) tumor bed boost during breast conserving surgery for early breast cancer on breast cancer associated and non-breast cancer associated	155
Abstract 1013: Mechanistic role of nelfinavir as drug-repurposing strategy against high-grade serous ovarian cancer	154
Abstract 1001: Treatment of RB1-intact cancers with CDK4/6 inhibitor combination therapy	140
Abstract 1151: Targeting castration-resistant prostate cancer using mesenchymal stem cell exosomes for therapeutic microRNA let-7c delivery	140
Abstract 2916: Characterization of a mouse model of leptomeningeal melanocytic disease	132
Abstract 2575: Intermittent calorie restriction reverses the adverse effects of obesity and advanced age on tumor growth in a mouse model of breast cancer	127
Abstract 2884: Wnt11 dictates the patterns and latency of pulmonary micrometastatic disease in pancreatic cancer	127
Abstract 1221: The landscape of 2,706 RET alterations from 89,754 adult patients with cancer: Clinical implications	123
Abstract 1235: Selective androgen receptor degraders for the treatment of androgen receptor-positive, triple-negative breast cancer	120
Abstract 2650: Angiogenic inhibitors reduce mycosis fungoides cell survival and enhance cell death	118
Abstract 2945: Novel engineered B-NDG B2M/KO mice plus and steroid treated B-NDG Mice shows delayed GvHD response when engrafted with hPBMC	117
Abstract 2481: Time-resolved transcriptome analysis of murine TH-MYCN driven neuroblastoma identifies MEIS2 as early initiating factor and novel core gene regulatory circuitry constituent	112
Abstract 2969: Impact of baseline culture condition on the growth and treatment response of mouse derived cancer organoids	111
Abstract 2648: A dual functional agent inhibits the angiogenesis and DNA synthesis resulting in the growth suppression of consensus molecular subtypes 1 and 4 in colorectal cancer xenografts	111
Abstract 2735: Clinical significance of CD4+CD7−helper T-cells and tumoral CD7 expression in colorectal cancer	109
Abstract 2957: A novel circulating tumor DNA (ctDNA) assay enables monitoring of disease progression and treatment response in disseminated preclinical hematologic cancer models	107
Abstract 2807: Variations in glycolytic activity of HCC subtypes as monitored by in vivo h 13C MRI	105
Abstract 2951: Anti-GCGR in vivo efficacy evaluated in a novel humanized B-hGCGR mouse model	103
Abstract 2574: Collagen density and obesity promote mammary gland inflammation	102
Abstract 317: Berberine-mediated reprogramming of the inflammatory environment in anaplastic thyroid cancer	102
Abstract 525: Novel DARPin multi-specific T-cell engager with an improved therapeutic window to overcome dose limiting toxicities in AML therapies	101

Abstract 3192: PD-L1 is an independent prognostic marker in Middle Eastern PTC and its expression is upregulated by BRAFV600E mutation	100
Abstract 324: Unbiased proteomic and phosphoproteomic analysis identifies response signatures and novel susceptibilities after combined MEK and mTOR inhibition in BRAFV600E mutant glioma	91
Abstract 322: Protein expression shift and potential diagnostic markers through proteomics profiling of A549 lung cancer cells	90
Abstract 375: High tumor mutation burden predicts unfavorable clinical outcome in EGFR-mutated lung adenocarcinoma treated with targeted therapy	90
Abstract 1545: Development of FGFR4-targeted chimeric antigen receptors (CARs) for the treatment of rhabdomyosarcoma	89
Abstract 433: Clinical validation of a Dickkopf-1 (DKK1) chromogenic in-situ hybridization (CISH) assay for manual and image-analysis assisted pathologist interpretation	89
Abstract 184: The utility of deep metric learning for breast cancer identification on mammographic images	88
Abstract 1406: FOXC1 induces cisplatin resistance through enhancer activation in bladder cancer	88
Abstract 1366: Integrated population modeling of loncastuximab tesirine (Lonca) exposure in B-cell non-Hodgkin lymphoma (B-NHL)	80
Abstract 1327: Role of intra-tumoral bacteria in EGFR-tyrosine kinase inhibitor resistance	78
Abstract 1305: Classification of cell morphology using machine learning and label-free live-cell imaging	78
Abstract 1381: Impact of PI3K/mTOR inhibitors on the development of taxane resistance	78
Abstract 133: Skeletal muscle transcriptome profiling of human pancreatic cancer cachexia: single largest study in cachexia	77
Abstract 1430: In vivo PoC study and design for Phase I clinical study of SJP1604, a nucleolin-targeted therapeutic agent to treat entire population of relapsed/refractory acute myeloid leukemi	77
Abstract 1479: Pan-cancer efficacy of BRAF and/or MEK inhibitors in BRAF V600-mutant multiple non-melanoma cancers: A clinico-genomic study	77
Abstract 1790: BO-112 as a modifier of the tumor microenvironment for liver metastases	77
Abstract 1634: Siglec-15 knockout inhibits tumor growth in mouse model	74
Abstract 1629: IO-202, a first-in-class LILRB4 antagonist antibody, activates dendritic cells and inhibits solid tumor growth in preclinical studies	73
Abstract 1513: A case study investigation into the role of CD4+ tumor-infiltrating lymphocytes in a metastatic melanoma patient with a complete response to adoptive cell therapy	72
Abstract 1896: The genomic features of Chinese cancer patients harboring HLA LOH	72
Abstract 1324: Evaluation of KIF14 in a chemotherapeutic resistant breast cancer cell line	70
Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative l	70
Abstract 1587: Generation and characterization of novel bispecific molecules combining single-chain-CD40L with anti-CEA, anti-CD95L or anti-PD-L1 targeting moieties	70
Abstract 1980: Non-canonical regulation and function of anti-apoptotic protein c-FLIP	70
Abstract 1362: Exposure-response (E-R) analysis of efficacy for avelumab as first-line maintenance therapy for urothelial carcinoma in the JAVELIN Bladder 100 study	70
Abstract P3-20-09: Surgery vs radiation therapy as the first stage treatment in patients with locally advanced breast cancer with incomplete clinical response	69
Abstract P5-08-02: MORAb-202, an antibody-drug-conjugate (ADC) targeting folate receptor alpha (FRα), exhibits durable anti-tumor efficacy in PDx models of TNBC	68
Abstract P4-01-16: Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR	67
Abstract CT144: Development of GMI-1359, a novel agent targeting tumor-microenvironment cross-talk in bone metastatic cancer	67
Abstract P3-12-20: Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+ early stage breast cancer	67
Abstract LB071: Tuning the tumor myeloid microenvironment (TME) by targeting TREM2+ tumor-associated macrophages to overcome resistance to immune checkpoint inhibitors	66
Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy	66
Abstract OT2-21-01: A randomized, multicenter pragmatic trial comparing bone pain from a single dose of pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adj	66
Abstract PD3-03: EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression	66
Abstract 2126: Therapeutic potential of CPI-0209	65
Abstract 3175: FAT1 and the immunosuppressive milieu in glioblastoma tumors	65
Abstract P4-11-16: Feasibility and patient satisfaction with a smartphone application to improve medication adherence among patients with breast cancer	65
Abstract P4-05-09: Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience	63
Abstract P3-18-14: Assessment of quality of life and objective cosmetic outcome of breast conserving surgery with or without latissimus dorsi mini-flap in breast cancer	63
Abstract P4-10-10: Effectiveness and feasibility of exercise-oncology programs in breast cancer patients using new technologies adapted to the COVID 19 new normality	62
Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS	61
Abstract P1-08-09: High mid-treatment RNA disruption in patients with HER2-negative breast cancer predicts survival benefit after neoadjuvant chemotherapy	61
Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with	60
Abstract P4-11-05: How to stay sexually active and sexually well-functioning after breast cancer - Reporting from the SWEET study	60
Abstract ES8-2: Can radiation replace ALND after positive SLNB?	59
Abstract P1-06-01: Insights from rapid autopsy shed light on mechanisms of cancer dissemination in metastatic breast cancer	59
Abstract P5-14-10: Examining inequities associated with incarceration among patients with breast cancer	59
Abstract NG14: Reduction in mitochondrial priming drives resistance to targeted therapy in acute myeloid leukemia	59
Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast	58
Abstract 864: Changes over time in real-world next-generation sequencing (NGS) test use in patients (pts) with advanced non-small cell lung cancer (aNSCLC)	58

Abstract 442: Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189	58
Abstract P5-13-17: PD-L1 expression in breast to brain metastases	57
Abstract PD4-03: Characterization of HER2 amplification in the cerebrospinal fluid of patients with Leptomeningeal Disease in stage IV patients with breast cancer	57
Abstract 867: Incidence of molecular alterations in KRAS and other known cancer genes in patients with pancreatic cancer assessed with a commercial genomic profiling panel compared to TCGA results	57
Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer	56
Abstract P4-12-14: Assessing patients perceptions on hormone therapy for breast cancer: Insights from a Brazilian patient group	56
Abstract 1220: Selective and broad anti-tumor activity of AKR1C3-activated prodrug AST-3424/OBI-3424	56
Abstract 715: Flow cytometry analysis of immune response to COVID-19 vaccine candidates using an in vitro stimulation model	55
Abstract 2048: Property analysis of chromosomal instability-adapted cells using multi-omics approaches	55
Abstract 2030: Oncological relevance of protein hydroxylase inhibitors (PHI): results of testing an emerging concept with an orally active pioneer medicine that blocks the hydroxylations of proline an	55
Abstract 407: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response	55
Abstract 3193: Development and functional characterization of NC762, a novel therapeutic antibody targeting B7-H4, for the treatment of malignancies	54
Abstract 532: Association of pCR and the 8-gene signature: NRG Oncology/NSABP B-41	54
Abstract 494: Novel human B7-H3 knock-in mice demonstrate efficacy of anti-B7-H3 immunotherapy in vivo	54
Abstract 3165: Stroma-immune landscape in lymphoma: new mechanisms of immunosuppression and therapeutic targeting	53
Abstract 2338: The GLS1 inhibitor IPN60090 enhances antitumor immune response through metabolic reprogramming of T cells and impacts on the tumor microenvironment	52
Abstract 893: Batch effects in tumor biomarker studies using tissue microarrays: Extent, impact, and remediation	52
Abstract 845: Association of nut consumption with risk of total and specific cancers: Evidence from three large prospective cohort studies	52
Abstract 2535: Leukemic Cell Proteomic Profiling in Pediatric AML	51
Abstract 856: Proteomic analysis of serum in workers exposed to diesel engine exhaust	51
Abstract 2433: Core regulatory circuits of clear cell ovarian and kidney cancers	51
Abstract 2333: EMT programs ovarian cancer cells to survive the adipocyte-rich microenvironment	51
Abstract 2457: NANOG bindsPRC2 to reprogram metabolismandpromotelabel-retaining populationin experimental mouse and clinical carcinoma	50
Abstract 810: Enrichment and screening of LFS patients by analyzing TP53 germline mutations of a Chinese cancer cohort	50
Abstract 902: Contributions of cancer treatment, comorbidities and obesity to aging-related diseases risks in B-cell non-Hodgkin's lymphoma survivors	50
Abstract 2592: Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer	50
Abstract 986: Induction of lytic cycle of Epstein-Barr virus by a novel organic compound through activation of the c-Jun N-terminal kinase pathway	49
Abstract PO-119: DFMO mediated improvement in survival of an orthotopic model of pancreatic cancer is associated with modulating immune suppression in the tumor microenvironment	49
Abstract 2260: Evaluating a rare t(X;14)(q28;q32) translocation reveals MTCP1 as a driving factor in chronic lymphocytic leukemia	49
Abstract 740: A robust rapid mRNA based test to profile simultaneously ER, AR, PI3K and MAPK functional signaling pathway activity for precision oncology	49
Abstract NG09: Bioengineered tissue mimetic hydrogels to study brain tumor biology and screen therapeutics	49
Abstract LB179: Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastroint	49
Abstract 2331: Metabolic evasion of mCRPC immunotherapy by ACOD1 production of itaconate	49
Abstract LB072: SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus	49
Abstract LB188: RNA-seq and chIP-seq profiling identifies genes and pathways dysregulated by hey1-ncoa2 fusion and shed a light on mesenchymal chondrosarcoma tumorigenesis	49
Abstract 905: Investigating the effects of aerobic exercise on preclinical breast cancer outcomes	49
Abstract 1342: Development and preclinical evaluation of unique first-in-class small molecule inhibitors of the anti-apoptotic protein FLIP	48
Abstract 1472: Novel EGFR WT sparing, HER2 selective inhibitors for the treatment of HER2 exon 20 insertion driven tumors address a clear unmet medical need	48
Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies	48
Abstract LB129: Stratification of radiotherapy and fluoropyrimidine-based chemotherapy from multi-omic profiling in rectal cancer biopsies	48
Correction: Mitochondrial DNA Repair through OGG1 Activity Attenuates Breast Cancer Progression and Metastasis	48
Editor's Note: p38 Mitogen-Activated Protein Kinase-Driven MAPKAPK2 Regulates Invasion of Bladder Cancer by Modulation of MMP-2 and MMP-9 Activity	47
Hyperactive Dendritc Cells Redirect Aged Antitumor Immunity	47
Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma	47
A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants	46
Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer	46
Abstract 207: The cBioPortal for Cancer Genomics	45
Stayin' Alive: Targeting Chromatin Regulators of Clonal Hematopoiesis Promotes CD8 T-cell Stemness	45
Abstract P1-18-17: Phase I study of cfi-402257, an oral ttk inhibitor, in patients with advanced solid tumors with breast cancer expansion cohorts	45
The Warburg Effect Revisited through Blood and Electron Flow	44
Abstract 2449: FGFR4 inhibitor BLU9931 induces cellular senescence in pancreatic ductal adenocarcinoma cell lines promoting sensitivity to senolytic therapy	44
Abstract CT023: PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM)	44
Abstract 3107: HSB-1216, A Novel Agent for the Treatment of Chemotherapy-Resistant ES-SCLC	44
Abstract 2391: Computation of a user-friendly composite score from three prostate cancer biomarkers	43
FOXP4 Is a Direct YAP1 Target That Promotes Gastric Cancer Stemness and Drives Metastasis	43
NCI Cancer Research Data Commons: Core Standards and Services	43
Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL	43
Abstract 3054: Synergistic activity of DNA damage response kinase inhibitors in combination with the targeted alpha therapy radium-223 dichloride for metastatic castration-resistant prostate cancer	43
Abstract 588: Mesenchymal markers: The new avenue for circulating tumor cells detection	43
Abstract 528: MDSC suppress the T cell repertoire and contribute to a pathologic cytokine milieu in cancer patients	43
Abstract P5-01-03: Mouse-intraductal (MIND): An in vivo model for studying the underlying mechanisms of DCIS malignancy	43
Abstract SY17-03: Tumor-associated antigen MUC1 vaccine for colon cancer prevention	43
Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity	42
Abstract 2074: MALDI-ICC: a new tool for high-plex, multiomic profiling of single cells for cancer research and cancer therapy	42
PROX1: a key regulator of hepatocyte identity and tumorigenesis	42
Abstract 1273: Advancing precision oncology: Development and utilization of breast cancer PDX models for in vivo drug discovery	41
Abstract 3371: Gene deletions in estrogen receptor positive HER2-negative breast cancer are associated with worse outcome than predicted by diagnostic-grade gene expression assays	41
Abstract 1320: Nanotopographical cues enhance glioblastoma migration: Harnessing biomimetic matrices and machine learning to uncover cancer invasion	41
Abstract 3727: Physical activity patters according to demographic, social, and clinical correlates among breast cancer survivors	41
Abstract 3688: Correlation between natural killer cell sensitivity and epithelial mesenchymal transition morphology: A cell morphology based screening for NK cell susceptible tumor cells	41
Abstract 294: TFEB nuclear persistence predicts sensitivity to lysosomal inhibition in therapy-induced senescent thyroid cancer cells	41
Abstract 3731: The role of dietary patterns and microbiome composition in colorectal cancer survival: The ColoCare Study	41
Abstract 1913: Cystic fluid acetylated polyamines predict risk of malignancy of intraductal papillary mucinous neoplasms of the pancreas	41
Abstract 1124: Mining the Kras-p53 mutational interface for synthetic lethality (SL) in pancreatic adenocarcinoma (PA)	41
Abstract 424: Chromosomal instability leads to EGFR-TKI refractoriness via cGAS-STING activation in EGFR-mutated non-small cell lung cancer	40
Abstract 1120: Baseline biomarker analyses of patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the phase 3 CodeBreaK 300 study	40
Abstract 47: Optimizing in vivo establishment of hormone receptor-positive breast cancer patient-derived xenografts for therapeutic assessment	40
Abstract 679: Orthogonal confirmation using the Pacbio®two step universal adapter amplicon protocol to validate a comprehensive genomic profiling assay for hematologic malignancies	40
Abstract 3655: Leveraging alternative AIML technologies to identify predictive biomarkers for chemotherapy selection: An analysis of the COMPASS trial evaluating chemotherapy response in advanced PDAC	40
Abstract 2873: Preclinical development of SMP-656: An eribulin-SuperHydraTM linker based ADC	40

Abstract 1510: Glutathione-oxidation of ovarian tumor deubiquitinase-1 promotes lung adenocarcinoma survival through stabilizing system xc-	40
Abstract 352: Preclinical development of MHB042C: A next-generation anti-c-Met ADC conjugating VHH-Fc fusion protein with a novel topoisomerase I inhibitor	39
Abstract 7210: Predicting drug response heterogeneity in AML: novel AI-enabled proteomics model for a prospective clinical trial	39
Abstract 515: Repurposing nebivolol with dasatinib and CPI-613: A synergistic strategy to combat triple-negative breast cancer	39
Abstract 7218: Preventive use of trilaciclib in Chinese patient with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy: A multi-center, single-arm, observational real-world study	39
Abstract 7085: Analysis of gene expression pattern of glycosphingolipid synthases using tumor tissues from breast cancer patients to identify key targets for early diagnosis and protection of recurren	39
Abstract 524: An integrative approach to unveiling biomarkers and therapeutic targets identifies novel treatment strategy for advanced prostate cancer	39
Abstract 7502: Radiation-induced transcriptomic reprogramming of mesenchymal glioblastoma stem cells reveals key pathways and potential targets	39
Abstract 365: A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma	38
Abstract 691: Decentralized pan-cancer tumor profiling: a comprehensive performance evaluation of the MSK-IMPACT® Assay with SOPHiA DDMTM	38
Abstract 244: Identification of proteins in the oncogenic FLT3-ITD signaling pathway using the APEX2 system	38
Abstract 611: Actinobacteria from macroalgae as a source of new anti-lymphoma compounds	38
Abstract 115: S-adenosyl-methionine (SAM) synthesis protects ovarian cancer from chemotherapy induced DNA damage and contributes to cancer stem cell enrichment	38
Abstract 768: Decode the antibody-drug conjugate surfaceome in metastatic urothelial cancer (DECODE-ADC)	38
Abstract 1072: MOSAIC Window: Spatial intra-tumoral heterogeneity characterization through large-scale spatial and single-nuclei multi-omics profiling	38
Abstract 817: A prospective, multi-center, phase IV study to evaluate safety and efficacy of Dr. Reddy’s bevacizumab (DRL_BZ) in patients with solid tumors	38
Abstract 1585: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model	38
Abstract 1108: Tissue and circulating DNA methylation profiling can recapitulate SCLC heterogeneity to enable identification of new biomarkers of clinical relevance	38
Abstract 2651: Nuclear prothymosin α suppresses TGF-β-induced EMT by stabilizing smad7: implications for lung cancer progression and metastasis	37
Abstract 6096: Acquired CAR-T therapy resistance in a pre-clinical model of pediatric rhabdomyosarcoma minimal residual disease	37
Abstract 6063: ROSE12, a novel anti-CTLA-4 Switch antibody™ with FcγR affinity-enhanced Fc, evokes tumor-selective anti-tumor immune activation by extracellular ATP without systemic immune activation	37
Abstract 5166: Increasing translatability of syngeneic mouse models of cancer through the application of human-validated, clinically relevant gene expression-based measurements of the tumor immune mic	37
Abstract 1066: OncoKBTM, MSK’s precision oncology knowledge base: 2024 updates	37
Abstract 6095: T-PureTM: A bispecific antibody cocktail for T cell isolation from human blood, enabling simple and affordable point-of-care CAR-T manufacturing	37
Abstract 5726: QLS1103, A highly potent and selective PARP7 inhibitor treating advanced solid tumors	37
Abstract 1520: Obesity delays melanoma resistance to BRAF/MEKi inhibitors and alters melanoma metabolism	37
Abstract 4822: Efficacy of 4-1BB-costimulated NKG2D CAR-T cells for synovial sarcoma in comparison with CAR-T cells targeting other antigens	37
Abstract 6681: Identification of a panel of four exosomal microRNAs driving T cell dysfunction in the tumor-immune microenvironment of high-grade serous ovarian cancer	36
Abstract 7004: CT7439 an oral first-in class selective CDK12 and 13 inhibitor and cyclin K degrader: Profiling activity and combination efficacy in an ovarian cancer model	36
Abstract 7205: Targeting diverse pathways for the treatment of KRAS driven non-small cell lung cancer	36
Abstract 3434: Evaluation of TCR-engineered T cells specific for KRAS G12V mutant peptide presented by HLA-A*02:01	35
Abstract 88: Ephrin receptor A4 is a regulator of metastatic colonization in triple negative breast cancer	35
Abstract 7180: DNA methylation profiling of peripheral blood mononuclear cells from small-cell lung cancer patients treated with hypomethylating agent plus carboplatin	35
Abstract 140: Profiling ECM biomarkers PRO-C3 and PRO-C5 in plasma from patients with esophagogastric cancer	35
Abstract 1348: Investigation of sex disparity in hepatocarcinogenesis using a hydrodynamic tail vein injection mouse model	35
Abstract 3358: Tertiary lymphoid structures (TLS) estimated by AI tools from digital H&E slides significantly enhance survival prediction in high-risk AJCC stages III/IV melanoma	35
Abstract 7326: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases	35
Abstract 2119: Targeting KIT in chromophobe renal cell carcinoma	35
Abstract 6198: Framework for Pacific Island Cancer and Obesity Across the Lifespan: PICOLI, A multi-dataset analysis approach	34
Abstract 3915: An orthotopic model for murine urothelial carcinoma with response to standard of care checkpoint inhibitor treatment	34
Abstract 4286: CHK1 as a novel therapeutic target for pleural mesothelioma	34
Abstract 2804: Long non-coding RNA LINC01614 regulates ferroptosis-mediated carcinogenic phenotypes in papillary thyroid cancer	34
Abstract 2056: Development of a response prediction Model for venetoclax-based therapy utilizing molecular interactions among BCL2 family members	34
Abstract 72: A case of immune therapy-refractory composite lymphoma: The complex interplay between two distinct tumors within a single spatial microenvironment	33
Abstract 904: Mapping the T cell-cold phenotype to the colorectal cancer genome identifies POFUT1 as a driver of tumor T cell inhibition	33
Abstract 1719: Constitutive aryl hydrocarbon activity promotes resistance to bortezomib which is exacerbated by leptin and potentially involves Src phosphorylation by JAK2 in prostate cancer cells	33
Abstract 3045: Development of a first-in-class PDIA6/IRE1 modulator for selectively sensitizing cancer cells to ER stress and regulated cell death	33
Abstract 713: Utility of next generation sequencing multigene assay for comprehensive molecular profiling and targeted therapy in solid organ malignancies - An Indian experience	33
Abstract 4173: Compensatory interactions between tryptophan catabolism and serine metabolism highlight potential vulnerabilities in TNBC cells with dysregulated de novo serine synthesis	33
Abstract 1168: ADAR1 synthetic lethality in BRCA1/2-mutant tumors defines autocrine interferon poisoning as a targetable vulnerability of cancer cells	33
Abstract 988: Impact of the COVID-19 pandemic on HPV vaccine hesitancy	33
Abstract 5105: Tumor treating fields (TTFields) alter nanomechanical attributes of cell-ECM complex in pancreatic ductal adenocarcinoma	33
Abstract 1086: Introducing the Florida Cancer Research (FL CARES) Network and the Platform for Accelerating Collaborative Computational Cancer Research (PAC3R)	32
Abstract 2485: A Bayesian framework for unraveling disease biology from spatially resolved single-cell omics datasets by combining unbiased approaches with biological priors for cell-based microdomain	32
Abstract 7388: Trends of diagnosis disclosure among individuals with plasma cell disorders	32
Abstract 4686: Efficacy and safety of efbemalenograstim alfa as primary prophylaxisfor concurrent chemo-radiotherapy induced neutropenia	32
Abstract 2486: Decoding tumor evolution through fitness landscapes of aneuploid cells	32
Abstract 7446: Stratification of cell therapies in solid tumor organoids using deep learning-derived imaging metrics	32
Abstract 7035: Targeting Ewing sarcoma with a novel RBM39 degrader: DNA damage repair pathway effects	32
Abstract 1470: Inhibition of protein myristoylation sensitizes pancreatic cancer cells to DNA damage agents	32
Abstract 7374: Body size and composition in relation to PI3K/AKT/mTOR signaling: insights into cancer risk and outcomes - a systematic review	32
Abstract 5365: Comparison of whole genome sequencing and target capture sequencing in lung cancer	32
Abstract 4575: mRNA expression in paired saliva and blood samples from different cancer indices	31
Abstract 7131: Integrative single-cell transcriptomic and epigenomic immune profiling reveals parallel insights into cancer research	31
Abstract 1843: Therapeutic implication of pH/hypoxic responsive nanoencapsulated tunicamycin on pancreatic cancer by targeting K-RasG12D	31
Abstract 7211: Proteolysis targeting chimeras (PROTACs) of oncogenic RET protein	31
Abstract 3005: Discovery of a potential therapeutic mechanism for selected tumors via targeting PI3K and DDR pathways simultaneously with a novel orally available small molecule	31
Abstract 4217: Effect of HDAC3 targeting on endometrial cancer progression and therapeutic potential	31
Abstract 6271: Interactions between CD8+ T cells and tumor cells decode tumor heterogeneity and provide treatment recommendations for colorectal cancer	31
Abstract 4454: Cancer cell permeability induced by tumor treating fields (TTFields) improves chemotherapy uptake and requires cells to transverse through the G2/M phase under TTFields application	31
Abstract 3793: Advancing GPC3-positive solid tumor therapy with AZD9793, a novel CD8-guided T cell engager with potent pre-clinical efficacy and superior therapeutic index over GPC3 x CD3 formats	31
Abstract 2232: BGB-R046, an IL-15 pro-drug demonstrates robust pharmacodynamic effects and immune activation within tumor microenvironment in a mouse syngeneic model	31
Abstract 3849: Pygo2 deletion stimulates tertiary lymphoid structure formation and forms the cornerstone for a quadruple combination immunotherapy of prostate cancer	30
Abstract 242: Differential activation of TAM receptors by Gas6 and protein S	30
Abstract 1718: Role of IKKε in resistance to second-generation hormone therapy in prostate cancer	30
Abstract 3510: A 2+1 format MUC16 targeting T cell engager induces MUC16-dependent T cell activity and superior anti-tumor efficacy	30
Abstract 3887: Clonal expansion in the bile duct associated with primary sclerosing cholangitis	30
Abstract 4772: AI-guided engineering and preclinical development of biparatopic anti-DLL3 antibody-drug conjugates (ADCs)	30
Abstract 2696: Targeting SLC7A11 creates a favorable immune microenvironment in colorectal cancer	30
Abstract 2954: CS5007: A novel EGFR and HER3 dual-targeted antibody-drug conjugate (ADC) with potent antitumor activity in preclinical studies	30
Abstract 3603: Racial and ethnic disparities in colorectal cancer-specific mortality: The Multiethnic Cohort	30
Abstract 5690: Targeting MET activation in CDH1 deficient diffuse gastric cancer with peritoneal metastases	30
Abstract 5761: Unbiased phosphoproteomic and metabolic profiling in WT and KRAS mutant colorectal cancer cells reveals molecular interplay between protein regulation and metabolic rewiring	30
Abstract 4192: Preclinical characterization of LAE122, a novel, potent and selective WRN inhibitor for the treatment of MSI-H tumors	30
Abstract 3261: Plasma whole-genome sequencing to monitor pancreatic cancer	30
Abstract 6327: Prevention of glioblastoma cell growth by Vialinin A	29
Abstract 5750: Discovery of GSK4418959 (IDE275): A novel, non-covalent, reversible Werner Helicase inhibitor and a new potential therapeutic for the treatment of MSI-H cancers	29
Abstract 5131: Dysregulated cholesterol metabolism facilitates epithelial-to-mesenchymal transition and tumor progression in colorectal cancer	29
Abstract 2933: IDP-001 is a potent bispecific ADC with in vivo activity against mouse xenograft tumor models expressing EGFR and CDCP1	29
Abstract 6297: Mapping cellular interactions from spatially resolved transcriptomics data	29
Abstract 5887: NALCN promoter methylation as a biomarker for metastatic risk in a cohort of non-small cell lung cancer patients	29
Abstract 4224: The pharmacological intervention of protein arginine methyltransferase 1 (PRMT1) leads to metastatic castration-resistant prostate cancer (mCRPC) repression through unique and significa	29
Abstract 2250: UCHL1 hijacks tolerogenic DC maturation and promotes mregDC-Treg crosstalk to nullify anti-PD-L1 therapy	29
Abstract 3848: Smoking promotes angiogenesis and epithelial to mesenchymal transition in breast cancer	29
Abstract 3997: Advancing precision cancer medicine with patient-derived organoids: an endometrial cancer case study	29